Koers Capricor Therapeutics Inc Nasdaq
Aandelen
US14070B1017
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 21,4 mln. 20,01 mln. | Omzet 2025 * | 89,52 mln. 83,72 mln. | Marktkapitalisatie | 170 mln. 159 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -33 mln. -30,86 mln. | Nettowinst (verlies) 2025 * | 8 mln. 7,48 mln. | EV/omzet 2024 * | 7,96 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,9 x |
K/w-verhouding 2024 * |
-5,61
x | K/w-verhouding 2025 * |
55,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,8% |
Recentste transcriptie over Capricor Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20-11-13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20-11-13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21-07-23 |
Earl Collier
BRD | Director/Board Member | 76 | 20-11-13 |
George Dunbar
BRD | Director/Board Member | 77 | 20-11-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |